Carregant...
Fitxers
Tipus de document
TesiVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/105457
Role of TGFβ family members on physiological angiogenesis and ovarian cancer
Títol de la revista
Autors
ISSN de la revista
Títol del volum
Resum
[eng] Role of TGFβ in physiological angiogenesis and ovarian cancer Transforming Growth Factor Beta (TGFβ) is a signalling pathway involved in a wide range of cellular processes such as proliferation, differentiation, angiogenesis, migration and homeostasis. In addition, it has been broadly related with pathological situations like cancer or other diseases. In this thesis we have been focused on two of its receptors; the TβRI called ALK5, ubiquitously expressed, and ALK1, an endothelial cell-restricted receptor. In the first part of this work we have studied the role of ALK1 in angiogenesis. Loss of function mutations in ALK1 cause a subtype of hereditary haemorrhagic telangiectasias (HHTs) characterized by vasculature malformations. Currently, there is no suitable treatment to cure these patients. To study the ALK1 role in vascular development, we have used the retina mouse model and seeking to find a treatment for these patients, we have used a mouse model for HHTs. This mouse model has a heterozygous alteration in ALK1, as in homozygosis die at +/- mice resulted in abnormal endothelial cell proliferation mid-gestion. The alteration on ALK1 and increased retinal vessel width without affecting pericyte coverage, migration or elongation of the ECs. We have shown that genetic and pharmacological inhibition of PI3K signalling +/- abolished the increase in vessel width in ALK1 retinas and normalized vasculature. Overall, our results suggest the potential for using PI3K inhibitors as new therapeutic agents for treating HHTs. In the second part of this work we have searched for new therapeutic targets for treating epithelial ovarian cancer. Firstly, we analysed the TGFβ signalling pathway in these tumours. Using a Tissue Micro Array (TMA) with patient samples we found high Smad2 phosphorylation, a read-out of ALK5 activation, in epithelial ovarian cancer tumoral cells, independently of tumour subtype (high-grade serous or endometrioid). To evaluate the impact of TGFβ receptor inhibition on tumoral growth, we used different models of human epithelial ovarian cancer orthotopically grown in nude mice (OVAs); two high-grade serous carcinoma and one endometrioid carcinoma. We have confirmed that the histological properties and the levels of phosphoSmad2 expression pattern were maintained on the ovarian tumour mouse models compared to its human primary tumours samples. Treatment with a TGFβRI&II dual inhibitor, LY2109761, caused a significant reduction in tumour size in all these models, affecting cell proliferation rate. On the contrary, TGFβ inhibition did not affect ovarian tumour cell capacity to disseminate in our models. We identified Insulin Growth Factor (IGF)1 receptor as the signal positively regulated by TGFβ implicated in ovarian tumour cell proliferation. We have demonstrated that our TMA samples had high IGF1R protein levels and that phosphoSmad2 and IGF1R protein levels significantly positively correlated. Inhibition of IGF1R activity by treatment with a blocker antibody (IMC- A12) or with a tyrosine kinase inhibitor (linsitinib) inhibited ovarian tumoral growth in vivo. At the molecular level TGFβ signalling positively controls IGF1R levels by two mechanisms. Induction of mRNA IGF1R levels in some cell lines or tumour samples, whereas a change on IGF1R protein localization was observed in others. In fact, TGFβ inhibition decreased IGF1R protein levels by controlling its stability; increasing IGF1R internalization and degradation through the lysosome. When IGF1R levels were decreased by shRNA treatment, ovarian cancer cell lines grew less and LY2109761 lost its capacity to block tumoral ovarian cell proliferation. Overall, our results suggest an important role for the TGFβ signalling pathway in ovarian tumour cell growth through the control of IGF1R signalling pathway. Moreover, it identifies anti-TGFβ inhibitors as being of potential use in new therapies for ovarian cancer patients as an alternative to IGF1R inhibition, being used in clinical trials.
Descripció
Matèries
Matèries (anglès)
Citació
Citació
ALSINA SANCHÍS, Elisenda. Role of TGFβ family members on physiological angiogenesis and ovarian cancer. [consulta: 2 de desembre de 2025]. [Disponible a: https://hdl.handle.net/2445/105457]